Archives

Aims & objective

  • To find out the known as well as some new factors which increase the risk of occurrence of stroke (half body paralysis, Lakwa) and of memory problem and other brain related problems.
  • To identify a group of apparently healthy people (50 years and above), carry out their health check up and follow them up over several years to detect any health problems (like heart attack, lakwa, memory problems) with increasing age.
  • To investigate the prevalence and incidence of and risk factors for stroke and cognitive decline in the elderly.

Updates about the health of the participants will be obtained from telephone follow-ups every six months and physical check-ups every three years. The study is expected to last for at least 10 years.

Last update – 02/02/2017

The AMPLE study has been set up to investigate differences and outcomes in those with Lewy body dementia with and without concurrent Alzheimer’s disease/pathology. The principle aim of AMPLE is to undertake amyloid PET imaging in Lewy Body Dementia (LBD) and Alzheimer’s disease (AD) of 80 participants over the age of 60 and investigate the distribution of amyloid burden in LBD relative to AD and controls at baseline. A further aim is to determine the relationship between amyloid levels at baseline, clinical features of the disease, other imaging changes and subsequent clinical course in follow up.

Primary analysis would divide LBD patients into high and low amyloid burden with participants then compared on clinical features with AD-like symptoms and cognitive profiles. Follow up will be completed annually through surveys and clinical examinations.

Last update – 01/02/2017

The overall goal was to establish a genetic-epidemiological database to shed light on the aging process among the extremely old, focusing on physical and cognitive functioning. In the first wave 2,262 Danes born in 1905 participated in a home-based 2-hour multidimensional interview, including cognitive and physical performance tests and collection of DNA, carried out by lay interviewers. Population-based registers were used to evaluate representativeness.

The first wave took place in 1998 and participants were followed-up in 2000 and 2003. In 2005 all the surviving birth cohort members were invited to participate irrespective of previous participation:

  • Wave 1: 2262 participants (1653 with biological sample)
  • Wave 2: 1086 participants
  • Wave 3: 437 participants
  • Wave 4: 256 participants

Last update – 30/01/2017

The DEAS is a nationwide representative survey of the German population aged 40 and older that combines cross-sectional and longitudinal samples. Participants from baseline samples (drawn every six years) are followed up and enter the different panel samples. Panel data was collected at the same time as baseline samples until 2008. Starting from 2011, panel samples are interviewed every three years. Thus, DEAS enables an analysis of social change using the cross-sectional data of 1996, 2002, 2008, and 2014, as well as an investigation of intra-individual development over three to eighteen years (1996-2002-2008-2011-2014).

Last update – 16/02/2017

The Dunedin Multidisciplinary Health and Development Study (DMHDS) is an ongoing, longitudinal study of the health, development and well-being of a general sample of New Zealanders. They were studied at birth (1972-73), followed up and assessed at the age of three when the longitudinal study was established. Since then they have been assessed every two years until the age of 15, then at ages 18 (1990-91), 21 (1993-94), 26 (1998-99), 32 (2003-2005), and 38 (2010-2012). It is planned to next see the Study members at age 44/45 and beyond.

Last update – 31/01/2017

GENFI is a five year longitudinal biomarker cohort study of genetic Frontotemporal Dementia and its associated disorders (including MND/ALS) investigating members of families with a known mutation in GRN or MAPT or an expansion in C9orf72 (including those affected with the disorder as well as at-risk members of families). Non-carrier first-degree relatives will serve as a control group.
All GENFI participants will be assessed longitudinally (annually) with a set of clinical, neuropsychiatric, cognitive, imaging and biosample protocols.

Last update – 25/01/2017

The HCS is a population-based cohort study established to assess factors important in the health, well-being, social functioning and economic consequences of ageing. The participants included community-dwelling men and women aged 55-85 years of age who reside in Newcastle, New South Wales (NSW), Australia. They were randomly selected from the NSW State electoral roll and contacted between December 2004 and December 2007.

The participants’ study data was collected through self-report postal questionnaires which covered a wide range of variables but also linked with local and national health information databases and hospital records. These provided follow-up on use of prescription medication, health service utilization and hospitalizations, morbidity and mortality. There was also a baseline clinic visit which measured a wide variety of parameters including hearing, vision, smell, balance, cognition, and lung function. Medications and diagnoses have been collected not only at baseline but also at periodic intervals during follow-up.

Last update – 31/01/2017

The main objective of the Longitudinal Ageing Study in India (LASI) is to provide comprehensive longitudinal evidence base on health, social and economic wellbeing of elderly population in India.

LASI main wave’s covers 30 states and 6 union territories of India covering a panel sample size of 60,250 elderly persons aged 45 years and above. The long-term goal of LASI is to continue this survey for the next 25 years with the first wave planned in the year 2016-17 and second wave in 2018-19. LASI aims to obtain all the indicators for each of the 30 states and 6 union territories. In addition, LASI aims at obtaining indicators for each of the four metropolitan cities of Delhi, Kolkata, Mumbai and Chennai.

Last update – 10/02/2017

The NIMROD (Neuroimaging of Inflammation in Memory and Other Disorders) study aims to understand the role of inflammation in several forms of dementia, memory loss and depression (Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), Parkinson’s disease dementia (PDD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), late life depression (LLD), mild cognitive impairment (MCI)). It also aims to understand the changes in the immune system, from immune cells and other components in the blood and cerebrospinal fluid.

To achieve this, NIMROD looks at brain changes in dementia, depression and related disorders in several different ways, detecting differences in brain structure and function, measuring inflammation and annual psychology and memory assessments. A further aim is to investigate if neuroinflammation can predict subsequent clinical course, including cognitive and functional decline.

Last update – 01/02/2017

The HELIAD is a population-based, multidisciplinary, collaborative study designed to estimate the prevalence and incidence of AD, other dementias, mild cognitive impairment, and other neuropsychiatric conditions of aging in the Greek population and to investigate associations between nutrition and cognitive dysfunction/age-related neuropsychiatric diseases in this Mediterranean population.

The participants in the HELIAD study were selected through random sampling from community-dwelling individuals over the age of 65 years in the cities of Larissa (located in the province of Thessaly in Central Greece and Marousi (located within the Athens Metropolitan area). The targeted sample of enrolled participants comprised approximately 2,500 individuals. No weighting or stratified sampling (according to age, gender, or education) was performed. Follow-ups with face-to-face interviews at ~3 year intervals.

Last update – 01/02/2017